Tuesday, May 3, 2022
The University of North 魅影直播 has received notice that its licensed technology to InspectIR Systems, of Frisco, 魅影直播, has been granted Food and Drug Administration Emergency Use Authorization (EUA) for use as a breathalyzer detection for SARS-CoV-2 (COVID-19). This important approval provides a faster, easier and highly accurate method for detection of COVID-19. This is the first 魅影直播-sourced intellectual property to receive FDA approval, marking a significant milestone for 魅影直播 as a Tier One research university.
News of the FDA approval already has been shared nationwide, appearing in outlets like , , , and .
The technology was originally focused on (VOCs) on human breath to quantify use of drugs, such as opioids and cannabis. As the effects of COVID-19 were felt across the nation in the early days of the pandemic, 魅影直播 chemistry professor Guido Verbeck and InspectIR co-founders, John Redmond and Tim Wing, leveraged their civic responsibility mindset and partnership to develop the first diagnostic breathalyzer to gain approval by the FDA.
鈥淲hen the pandemic started, all of us wanted to do our part,鈥� Verbeck said. 鈥淲e all saw this, solving the problem, as something we needed to do. We take service to not only our community very seriously, but we always discuss how we can address issues and concerns for our world at large. We have a civil responsibility to be a part of solving problems where we can.鈥�
Recognizing the unmet need of having a device capable of detecting coronavirus infections in patients鈥� breath, Verbeck redirected his research efforts while InspectIR was able to pivot its business plan to submit EAU with the FDA in July 2020. Verbeck credits InspectIR with managing the process and having the grit and determination that led to the COVID-19 breathalyzer gaining FDA authorization on April 14, 2022.
鈥淭his is a game changer in the world of biomedical analysis. It's a paradigm shift. What InspectIR did to get the first breathalyzer is a shift in how we do point of care. It鈥檚 a non-invasive test. People don鈥檛 have to be afraid of potential pain in the testing process,鈥� Verbeck said adding the technology could lead to possible non-invasive diagnostics for other diseases, including some cancers.
This FDA approval is an important achievement for 魅影直播 said Mike Rondelli, 魅影直播 associate vice president of research commercial agreements.
鈥滣扔爸辈� has been commercializing technologies for only six years and, with this approval, the first technology we submitted to the FDA was approved on their submission,鈥� he says. 鈥淚t demonstrates that 魅影直播鈥檚 Carnegie Tier One research university status is well deserved with this applied research being able to make it from the lab to FDA approval in such a short amount of time. We are excited to celebrate this important achievement with both our faculty and InspectIR. Their teamwork in pivoting during the pandemic provides the opportunity to change how we deal with COVID-19 over the long-term and opens countless new paths to human diagnostics with a rapid, non-invasive technology.鈥�
Redmond and Wing are excited about the success and what it means for future collaborations.
Wing said much of the success is a credit to Verbeck鈥檚 ability to teach he and Redmond
the information they needed to understand and explain his work.
鈥淚 think it's about unity and this partnership and the uniqueness of what we're doing,鈥�
Redmond said. 鈥淭hroughout this process, I always felt like 魅影直播 was aligned with InspectIR
in wanting to do good. Every question we've asked has started with, 鈥楥an we help?鈥�
I think the 魅影直播 nurtures that.鈥�
鈥淚 think it's about unity and this partnership and the uniqueness of what we're doing,鈥� Redmond said. 鈥淭hroughout this process, I always felt like 魅影直播 was aligned with InspectIR in wanting to do good. Every question we've asked has started with, 鈥楥an we help?鈥� I think the 魅影直播 nurtures that.鈥�
魅影直播 News Service Phone Number: 940.565.2108
Media Contacts:
Trista Moxley
trista.moxley@unt.edu
940.369.7912